關於 sustain6 ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes

由 WD Strain 著作 · 被引用 6 次 — SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) and PIONEER 6 ...

#12. SUSTAIN‐6: cardiovascular safety of a once‐weekly GLP‐1 ...

SUSTAIN-6 was a randomised, double-blind, placebo-controlled, parallel-group trial of 3297 patients at 230 sites in 20 countries, which studied ...

#13. cardiovascular safety of a once-weekly GLP-1 receptor agonist

PDF | On Oct 1, 2016, Ruth Cordiner and others published SUSTAIN-6: cardiovascular safety of a once-weekly GLP-1 receptor agonist | Find, ...

#14. Semaglutide treatment and renal function in the SUSTAIN 6 trial

Semaglutide treatment and renal function in the SUSTAIN 6 trial. Abstract # 78. Session: GLP1 receptor agonists, SGLT2 inhibitors and the kidney: new ...

#15. Semaglutide reduces the risk of MACE in SUSTAIN6 trial

The double-blinded SUSTAIN6 trial investigated the long-term cardiovascular and other safety outcomes of 0.5 mg and 1.0 mg semaglutide ...

#16. Effects of liraglutide and semaglutide on stroke subtypes in ...

LEADER (NCT01179048), SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) were global randomised cardiovascular (CV) outcomes trials of ...

#17. subcutaneous semaglutide and cardiovascular outcomes in ...

SUSTAIN-6 - subcutaneous semaglutide and cardiovascular outcomes in type 2 Diabetes. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 ...

#18. SUSTAIN 6 | 糖尿病トライアルデータベース - EBM-Library

SUSTAIN 6 ... Seufert J, Warren ML, et al.; SUSTAIN-6 Investigators: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

#19. SUSTAIN-6: Retinopathy complications may be increased with ...

SAN DIEGO — An analysis of data from SUSTAIN-6, the cardiovascular outcome trial of the glucagon-like peptide 1 receptor agonist semaglutide ...

#20. A POST HOC EXPLORATORY SUBGROUP ANALYSIS OF ...

Pooled SUSTAIN 6 and PIONEER 6 data were stratified by baseline MET use, and efficacy outcomes and MACE (3-point, expanded and individual ...

#21. Oral versus subcutaneous semaglutide for prevention of major ...

In SUSTAIN-6, After a median follow-up of 2.1 years, MACE occurred in fewer patients in the semaglutide group (HR 0.74, 95% CI 0.58–0.95). Among the individual ...

#22. Sustain 6 - LinkedIn

Sustain 6 | 279 followers on LinkedIn. Sustain 6 helps companies support their employees in becoming more personally sustainable.

#23. Sustain 6: Sustain Magazine for Luthiers: Lospennato, Leonardo

Sustain 6 : Sustain Magazine for Luthiers [Lospennato, Leonardo] on Amazon.com. *FREE* shipping on qualifying offers. Sustain 6: Sustain Magazine for ...

#24. American Society of Nephrology | Kidney Week

The SUSTAIN 6 cardiovascular outcomes trial (CVOT) indicated a benefit on kidney disease with subcutaneous (s.c.) once-weekly (OW) semaglutide vs placebo (PBO) ...

#25. SUSTAIN-6: Semaglutide improves cardiovascular outcomes ...

SUSTAIN-6 was a double-blind, randomised controlled trial in which adults with type 2 diabetes and high CV risk (either established CV ...

#26. Circulation on Twitter: "#OriginalResearch: In a pooled ...

#OriginalResearch: In a pooled analysis of the #SUSTAIN6 and #LEADER trials, #GLP1 receptor agonists were found to have renal-protective ...

#27. 簡介第2型糖尿病藥物治療指引更新 - 李氏聯合診所-季刊專欄

一週一次的semaglutide, albiglutide與dulaglutide分別在SUSTAIN 6[10], HARMONY[11]與REWIND[12] 研究中減少了3P-MACE約26%、21%與12%。這對於有心臟血管的糖尿病患者 ...

#28. New SUSTAIN-6 Data Could Explain Retinopathy Worsening

2017年6月10日 — SUSTAIN-6 was the second major cardiovascular-outcomes trial to show positive results for a GLP-1 agonist in type 2 diabetes patients at ...

#29. Semaglutide Treatment and Renal Function in the SUSTAIN 6 ...

This post-hoc analysis assessed the effect of semaglutide on renal function by baseline eGFR in the SUSTAIN 6 trial.

#30. Semaglutide and Cardiovascular Outcomes in Patients with ...

07 Jun Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes SUSTAIN-6 trial. Posted at 10:39h in Blogs by admin 0 Comments. Marso S.P. et al ...

#31. Update on SUSTAIN 6 trial among highlights of Acute and ...

The Acute and Chronic Complications track at the 77th Scientific Sessions includes more than two dozen symposia, state-of-the-art lectures, and special ...

#32. Sustain 6 (@sustain_6) • Instagram photos and videos

Sustain 6 helps companies support their employees in becoming more personally sustainable. linktr.ee/sustain6. 29 posts. 52 followers. 613 following.

#33. Cardiovascular outcome trials for diabetes drugs Semaglutide ...

SUSTAIN-6 confirmed non-inferiority for MACE, with nominal superiority, and demonstrated a significant reduction in the risk of non-fatal ...

#34. Can GLP-1 ra provide renal protection? - PACE-CME

SUSTAIN-6. - REWIND. ERA-EDTA 2020, Milano / online conference. Trials monitoring kidney events as spontaneous reports: - ELIXA. - EXSCEL.

#35. Semaglutide Cuts Risk of Major Cardiovascular Events in ...

SUSTAIN-6, along with the other cardiovascular outcomes studies with diabetic medications, was designed to meet the requirements set out by ...

#36. 新藥介紹：Semaglutide (Ozempic ) - 國泰綜合醫院

另一項試驗(SUSTAIN 6)則評估其心血. 管安全性，以心血管死亡、非致命性心肌梗. 塞或非致命性中風的發生作為主要觀察結果，. 觀察期間為2 年。

#37. SUSTAIN 6 - Novo Nordisk

5 The preapproval Trial to. Evaluate Cardiovascular and Other Long-term. Outcomes with Semaglutide in Subjects with. Type 2 Diabetes (SUSTAIN-6) ...

#38. Semaglutide降低糖尿病患者心血管風險

在一連串的實驗中，SUSTAIN-6是Semaglutide針對心血管疾病高危險群的糖尿病患者，比較是否有心血管風險增加的可能，而研究結果發現，Semaglutide可 ...

#39. Cardiovascular Benefit of Ozempic® (semaglutide) injection ...

SUSTAIN 6 —a 2‑year CVOT for Ozempic ... A 104-week, multicenter, multinational, placebo-controlled, double-blind CVOT in 3297 adult patients with inadequately ...

#40. Semaglutide reduces cardiovascular risk in diabetics

Semaglutide reduces cardiovascular risk in diabetics: The SUSTAIN-6 trial · 1. The two-year risk of developing cardiovascular death, nonfatal ...

#41. SUSTAIN6研究揭晓，降糖治疗新时代正在来临-MedSci.cn

SUSTAIN-6 研究旨在评估索马鲁肽治疗对2型糖尿病患者心血管事件以及其他长期结局的影响。本研究采用安慰剂对照设计，共纳入3297例≥50岁的2型糖尿病 ...

#42. A quick guide to the SUSTAIN trials - Medicine Matters diabetes

The results of SUSTAIN 6, published in The New England Journal of Medicine, showed a significant 26% reduction in the composite primary ...

#43. Novo Nordisk stokes GLP-1 hopes as weekly semaglutide ...

With 3,300 patients, SUSTAIN 6 involved just two years of treatment and was designed to prove safety rather than benefits. Victoza itself proved to cut the risk ...

#44. Semaglutide Treatment and Renal Function in the SUSTAIN 6 ...

Figure 1Change from baseline to the end of treatment in eGFR, stratified by baseline renal function in the SUSTAIN 6 trial.

#45. 降血糖藥物之心血管結果試驗：系統回顧及統合分析

events, MACE) (HR 0.88, 95% CI 0.82- 0.94)，其中SUSTAIN 6 (Semaglutide). (0.61, 0.38-0.99)及REWIND (Dulaglutide) (0.76, 0.61-0.95)可顯著下降腦中風風.

#46. Highlighting the major progress brought by semaglutide ...

Highlighting the major progress brought by semaglutide ( Sustain 6 and Pioneer 6). 410 views410 views. Apr 15, 2020.

#47. After the LEADER trial and SUSTAIN-6, how do we explain the ...

Diabetes & Metabolism - Vol. 43 - N° S1 - p. 23-212 - After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 ...

#48. Semaglutide and SUSTAIN-6: Another step towards the holy ...

Semaglutide and SUSTAIN-6: Another step towards the holy grail of type 2 diabetes management? Resource topics: Cardiovascular disease, Newer therapies. Date: 22 ...

#49. Applying REWIND cardiovascular disease ... - Europe PMC

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. · Author ...

#50. NN9535-3744 SUSTAIN 6 Semaglutide Cardiovascular ...

NN9535-3744 SUSTAIN 6 Semaglutide Cardiovascular Outcomes Study. Research type. Research Study. Full title. A long-term, randomised, double-blind, ...

#51. Sustain-6® (4lb) - ProLine Advanced Nutrition

Sustain-6 ® (4lb) · 6 HIGH QUALITY SUSTAINED RELEASED PROTEINS · FAST,MEDIUM,AND SLOW RELEASING PROTEINS · PROMOTES BUILDING OF LEAN MUSCLE & ENHANCES RECOVERY ...

#52. SUSTAIN 6 : une perte de poids constante au cours des 2 ans ...

L'étude de sécurité cardiovasculaire SUSTAIN 6, un essai randomisé et contrôlé versus placebo, a inclus 3297 sujets diabétiques de type 2 à haut risque ...

#53. SUSTAIN 6 - UCSF Fresno

SUSTAIN-6 Investigators. PUBLISHED. New England. Journal of Medicine. Ozempic® and cardiovascular outcomes in patients with type 2 diabetes.

#54. Peter Rossing, EASD 2022: The Effect of Semaglutide on Risk ...

SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE).

#55. reduction in the rate of egfr decline with semaglutide vs ...

Background and Aims The SUSTAIN 6 cardiovascular outcomes trial (CVOT) indicated that once-weekly (OW) subcutaneous (s.c.) semaglutide may ...

#56. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1 ...

In the randomised cardiovascular (CV) outcomes trials SUSTAIN 6 and LEADER, semaglutide and liraglutide improved CV and renal outcomes in patients with type ...

#57. ‪#‎sustain6‬ - Explore - Facebook

explore #sustain6 at Facebook.

#58. VEIC Licenses Sustainabli to Sustain 6

VEIC has entered into an exclusive licensing partnership of Sustainabli, its employee sustainability benefits platform, with Sustain 6.

#59. subcutaneous semaglutide and cardiovascular outcomes in ...

SUSTAIN-6 - subcutaneous semaglutide and cardiovascular outcomes in type 2 Diabetes. Last edited 12/2020 and last reviewed 10/2021.

#60. SUSTAIN 6: Uma promessa que se confirma - News Farma

O SUSTAIN-6 foi o segundo dos ensaios com agonistas do recetor GLP-1 apresentar resultados positivos na redução de eventos cardiovasculares em ...

#61. Semaglutide and Cardiovascular Outcomes in Patients with ...

The objective of the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) ...

#62. Sustain 6: Sustain Magazine for Luthiers - Goodreads

Sustain 6 book. Read reviews from world's largest community for readers. Sustain Magazine is a magazine for luthiers (builders of stringed ...

#63. Sustain 6 - Overview, News & Competitors | ZoomInfo.com

View Sustain 6 (www.sustain6.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as ...

#64. 第二型糖尿病生物製劑治療新進展 - BIOMEDICINE

SUSTAIN 6 試驗已證實semaglutide 有. 優異的降血糖與減輕體重功能( 圖一) 5，若欲. 探究藥物對體重相關作用機轉則可參考試驗. 3685，此試驗發現semaglutide 會顯著 ...

#65. Effects of once-weekly semaglutide on coronary outcomes in ...

... on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial.

#66. 「セマグルチド」が心血管イベント発生リスクの高い2型 ...

ノボ ノルディスクは、新規のGLP-1アナログである「セマグルチド」(週1回皮下注射剤)を標準治療に追加投与した試験「SUSTAIN 6」において、 ...

#67. SUSTAIN 6 彙整 - 曾耀賢醫師糖尿病・內分泌・大數據-

GLP-1 上市後的心血管結局研究(CVOT)，迄今完成共7項，分別有LEADER (Liraglutide QD SC); ELIXA (Lixisenatide QD SC); EXSCEL .

#68. 降血糖藥品之心血管事件探討 - 藥學雜誌電子報146期

... 致效劑之CVOT目前有exenatide的EXSCEL 11 、liraglutide的LEADER 12 、lixisenatide的ELIXA 13 、semaglutide的SUSTAIN-614 以及dulaglutide之REWIND 15 。

#69. Semaglutide treatment and renal function in the SUSTAIN 6 trial

Georg Thieme Verlag KG Stuttgart · New York. Semaglutide treatment and renal function in the SUSTAIN 6 trial. S Jacob. 1 Praxis f. Prävention und Therapie ...

#70. Novel Diabetes Drug Reduces CV Risk | MedPage Today

SUSTAIN 6 included 3,297 patients with type 2 diabetes on a standard diabetes care regimen randomized to once-weekly semaglutide (0.5 mg or ...

#71. Semaglutide Carries Potential Risk of Worsening Diabetic ...

In the SUSTAIN-6 trial, semaglutide showed a statistically significant 26% risk reduction in major adverse cardiovascular events (MACE) when ...

#72. SUSTAIN-6 | The British Journal of Cardiology

Tag Archives: SUSTAIN-6. In brief. November 2016 Br J Cardiol 2016;23:137. In brief. BJCardio Staff. Abstract. Physio-Control, a global leader in lifesaving ...

#73. Sustain 6 - Email & Phone of top management contacts

Sustain 6 - email id & phone of top management contacts like Founder, CEO, CFO, CMO, CTO, Marketing or HR or Finance head & all company details.

#74. 週1回皮下注射製剤のGLP-1受容体作動薬セマグルチドが2型 ...

SUSTAIN-6 試験は、心血管リスクの高い2型糖尿病患者3,297名を対象にセマグルチドの心血管アウトカムを検討したプラセボ対照無作為化二重盲検試験です。セマグルチド群には ...

#75. GLP-1 Receptor Agonists and Diabetic Kidney Disease - MDPI

The SUSTAIN 6 trial studied the effect of once-weekly treatment with 0.5 or 1 mg of long-acting semaglutide in 3297 T2DM.

#76. ASN abstract by Tuttle et al. Reduction in the Rate of eGFR ...

The SUSTAIN 6 cardiovascular outcomes trial (CVOT) indicated that once-weekly (OW) subcutaneous (s.c.) semaglutide may have beneficial effects on kidney ...

#77. Effects of semaglutide on stroke subtypes in type 2 diabetes

Methods: SUSTAIN 6 and ... ... Background: Glucagon-like peptide-1 receptor agonists, including semaglutide, may reduce stroke risk in people with ...

#78. Sustain 6 - Email Address & Phone Number - Lusha

Reach decision-makers at Sustain 6. Find their phone numbers & email addresses. It's free. - Lusha.

#79. Semaglutide Reduces Triglyceride Levels in Diabetic Patients

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.

#80. Effect of the Glucagon-Like Peptide-1 Receptor ... - Cronfa

Pooled (N=12,637) and by-trial data from SUSTAIN 6 (N=3297) and LEADER (N=9340) were assessed for albuminuria change, annual slope of estimated glomerular ...

#81. Now Novo Says Semaglutide Cuts CV Risk: SUSTAIN-6 Top ...

The Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6) examines the long-term ...

#82. After the LEADER trial and SUSTAIN-6, how do ... - HAL-Inserm

Recent cardiovascular outcome trials - the LEADER with liragutide and SUSTAIN-6 with semaglutide - have shown significant reductions of major cardiovascular ...

#83. Análisis del SUSTAIN 6 y PIONEER (Póster post hoc)

Análisis del SUSTAIN 6 y PIONEER (Póster post hoc) ... El Dr. Alfonso Freites Esteves comenta las conclusiones del póster publicado en AHA Scientific Sessions ...

#84. Semaglutide treatment and renal function in the Sustain 6 trial

Semaglutide treatment and renal function in the Sustain 6 trial. Research output: Contribution to journal › Conference abstract in journal › peer-review.

#85. SUSTAIN - 6 - Pharmacy Notebook

SUSTAIN - 6. Last edited 12/2020 and last reviewed 10/2021. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

#86. 司美格鲁肽和利拉鲁肽对糖尿病肾脏结局的影响SUSTAIN6和 ...

方法：利用SUSTAIN6（评价司美格鲁肽对2型糖尿病患者心血管和其他远期结局研究；3297人）和LEADER（利拉鲁肽在糖尿病中的效果和作用：评价心血管 ...

#87. SUSTAIN-6: Prevención de Eventos CV en pacientes DM2 ...

El ensayo SUSTAIN-6 se ha diseñado e implementado para averiguar si semaglutida es no inferior al placebo, y, si fuere no inferior, en qué ...

#88. SUSTAIN 6 | E-cordiam

SUSTAIN 6. Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in. Subjects with Type 2 Diabetes. Publication simultanée Marso SP ...

#89. (NEJM) Impacto de la semaglutida sobre las variables ...

(NEJM) Impacto de la semaglutida sobre las variables cardiovasculares en pacientes con DM2. Estudio SUSTAIN-6. 350x181xnadel_04-jpg-pagespeed-ic ...

#90. SUSTAIN-6 - Sociedad Española de Cardiología

SUSTAIN-6. Congreso Europeo de Diabetes: estudios de diabetes y enfermedad cardiovascular. Publicado: 23 septiembre 2016 | Categoría: CardioTV.

#91. After the LEADER trial and SUSTAIN-6, how do ... - ClinicalKey

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? ... 1 Introduction Glucagon-like peptide (GLP)- ...

#92. AR-GLP1 reducen el riesgo de ictus: análisis post Hoc de los ...

AR-GLP1 reducen el riesgo de ictus: análisis post Hoc de los estudios Sustain 6 y Pioneer 6 con Semaglutida.

#93. Ajman an environmentally friendly city with its quality of life

Sustain. 6, 9 (2021). Waste management strategy and development in Ajman, UAE Renew. Energy Environ. Sustain. 6, 14 (2021).

#94. Looking Ahead to New Packaging Material Innovation

Sustain 6. One of the UN sustainable development materials goals, according to a new report by PMMI Business Intelligence, is to increase the share of ...

#95. Is a GLP-1 Agonist in Tablet Form Safe for the Heart? - diaTribe

Why this is new/important: The SUSTAIN 6 clinical trial (completed last fall) found that an injected version of semaglutide may protect ...